| scholarly article | Q13442814 |
| P50 | author | Peter Riis Hansen | Q40522490 |
| P2093 | author name string | Klaus Bendtzen | |
| Klaus Rieneck | |||
| P433 | issue | 2-3 | |
| P304 | page(s) | 87-91 | |
| P577 | publication date | 2004-02-01 | |
| P1433 | published in | immunology Letters | Q15766068 |
| P1476 | title | Spironolactone inhibits production of proinflammatory cytokines by human mononuclear cells | |
| P478 | volume | 91 |
| Q30539790 | A pilot study of the effect of spironolactone therapy on exercise capacity and endothelial dysfunction in pulmonary arterial hypertension: study protocol for a randomized controlled trial |
| Q36643667 | Aldosterone inhibition reduces the risk of sudden cardiac death in patients with heart failure |
| Q46394312 | Effect of spironolactone on endothelial dysfunction in rheumatoid arthritis |
| Q47136214 | Effect of spironolactone on pain responses in mice |
| Q35100840 | Effects of spironolactone on human blood mononuclear cells: mineralocorticoid receptor independent effects on gene expression and late apoptosis induction |
| Q42833412 | Eplerenone inhibits tumour necrosis factor alpha shedding process by tumour necrosis factor alpha converting enzyme in monocytes from patients with congestive heart failure |
| Q31065780 | Ethinylestradiol30μg-drospirenone and metformin: could this combination improve endothelial dysfunction in polycystic ovary syndrome? |
| Q34328380 | Intrathecal injection of spironolactone attenuates radicular pain by inhibition of spinal microglia activation in a rat model |
| Q48317107 | Levels of NT-proBNP, markers of low-grade inflammation, and endothelial dysfunction during spironolactone treatment in patients with diabetic kidney disease |
| Q39230094 | Mineralocorticoid receptor blockade inhibits accelerated atherosclerosis induced by a low sodium diet in apolipoprotein E-deficient mice |
| Q26785911 | Modulation of Immunity and Inflammation by the Mineralocorticoid Receptor and Aldosterone |
| Q34576535 | Pharmacological and non-pharmacological interventions to influence adipose tissue function. |
| Q45928244 | Primary aldosteronism can alter peripheral levels of transforming growth factor beta and tumor necrosis factor alpha. |
| Q101578601 | Role of mineralocorticoid receptor antagonists in kidney diseases |
| Q36427277 | Spironolactone Effect in Hepatic Ischemia/Reperfusion Injury in Wistar Rats |
| Q58567686 | Spironolactone Protects against Diabetic Cardiomyopathy in Streptozotocin-Induced Diabetic Rats |
| Q54350807 | Spironolactone inhibits production of proinflammatory mediators in response to lipopolysaccharide via inactivation of nuclear factor-κB. |
| Q47647088 | Spironolactone-induced degradation of the TFIIH core complex XPB subunit suppresses NF-κB and AP-1 signalling |
| Q36526913 | Systemic inflammation in heart failure--the whys and wherefores |
| Q38256462 | The selective mineralocorticoid receptor antagonist eplerenone is protective in mild anti-GBM glomeru-lonephritis |
Search more.